Streetbeat News

Price Targets

NARI

Inari Medical (NASDAQ:NARI) has received mixed analyst ratings over the past three months, with 4 analysts offering diverse perspectives. The average 12-month price target for NARI is $73.00, with a high estimate of $85.00 and a low of $65.00, marking a slight increase from the previous target of $71.67. Analysts from Needham, Truist Securities, and Piper Sandler have adjusted their ratings and price targets, reflecting their latest views on the company's performance. Inari Medical, a medical device company, has shown strong financial performance with a revenue growth of 31.35%, a net margin of 2.5%, and an ROE of 0.71%. The company's market capitalization is below industry averages, but it has a low debt-to-equity ratio of 0.07.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 1:01 pm

IMNM

Wedbush analyst David Nierengarten has maintained an Outperform rating on Immunome (NASDAQ:IMNM) and increased the price target from $12 to $19.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:01 pm

MU

Micron Technology (NASDAQ:MU) has been evaluated by 33 analysts over the last three months, with a diverse range of opinions. The recent ratings show a shift towards a more bullish sentiment, with no bearish ratings in the last 30 days. Analysts have raised their 12-month price targets for MU, with an average target of $94.46, reflecting a 13.71% increase from the previous average of $83.07. The article also provides a detailed breakdown of individual analyst actions and their revised price targets. Micron's financial performance shows solid revenue growth but below industry benchmarks in net margin, ROE, and ROA, with a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 1:01 pm

SAFE

Safehold Inc. (NYSE:SAFE) has received mixed analyst ratings over the past three months, with 7 analysts offering a range of opinions. The average 12-month price target for SAFE is $28.14, representing an 11.67% increase from the previous target of $25.20. Analysts from firms including JMP Securities, Goldman Sachs, Jefferies, JP Morgan, Truist Securities, and RBC Capital have adjusted their ratings and price targets. Safehold's financial health indicators show positive revenue growth but below-average ROE and ROA, with a debt-to-equity ratio below the industry average.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 1:00 pm

BILL

BILL Holdings (NYSE:BILL) received mixed reviews from 9 analysts, with 3 bullish, 5 somewhat bullish, and 1 indifferent. The average 12-month price target is now $99.33, down 34.38% from the previous $151.38. Analysts from firms including Wells Fargo, Canaccord Genuity, Oppenheimer, Goldman Sachs, Susquehanna, Needham, and Piper Sandler have lowered their price targets for BILL, reflecting a cautious outlook on the company's financial performance. Despite a strong revenue growth rate of 32.65% for the quarter ending September 30, 2023, BILL's market capitalization is below industry benchmarks, and it has a net margin of -9.14%, an ROE of -0.68%, and an ROA of -0.29%, indicating profitability and asset utilization challenges.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 1:00 pm

ALKT

Eight analysts have recently provided their opinions on Alkami Technology (NASDAQ:ALKT), with sentiments ranging from bullish to indifferent. Over the past three months, the number of bullish and somewhat bullish ratings has decreased, while indifferent ratings have increased. The average 12-month price target for ALKT has been raised to $25.38, up 16.1% from the previous target of $21.86. Analysts from firms like Goldman Sachs, Keybanc, Needham, Barclays, Stephens & Co., JMP Securities, and JP Morgan have raised their price targets, reflecting a positive outlook on the company's performance. Alkami, a provider of cloud-based digital banking solutions, has shown a strong revenue growth rate of 26.76% as of September 30, 2023, but struggles with a net margin of -22.86% and an ROA of -3.24%, although it has an exceptional ROE of -4.8% and a low debt-to-equity ratio of 0.32.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 1:00 pm

DXCM

Over the past three months, 6 analysts have provided ratings for DexCom (NASDAQ:DXCM), with recent updates showing a positive trend in sentiment and an increase in the 12-month price target to an average of $134.5, up from $120.33. Analysts from firms such as Raymond James, Piper Sandler, Wells Fargo, and Morgan Stanley have raised their price targets, reflecting optimism about DexCom's financial health, which includes strong revenue growth, net margin, ROE, and ROA, despite some concerns over debt management.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 1:00 pm

CHRS

Truist Securities analyst Robyn Karnauskas has maintained a Buy rating on Coherus BioSciences (NASDAQ:CHRS) but reduced the price target from $12 to $8.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 12:53 pm

CHRS

Truist Securities analyst Robyn Karnauskas has maintained a Buy rating on Coherus BioSciences (NASDAQ:CHRS) but reduced the price target from $12 to $8.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 12:50 pm

DHI

Wedbush analyst Jay McCanless has reiterated a Neutral rating on D.R. Horton (NYSE:DHI) and maintained a price target of $115. The reaffirmation of the rating and price target suggests that Wedbush's outlook on D.R. Horton remains unchanged.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 12:49 pm